Company Overview
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Why Investors Should Care
Revenue has grown at a 38.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $18.62M (+70.9% YoY); net profit $-76.68M.
- Trailing 12 Months Year-on-year growth — revenue +1148.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 38.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 38.09% |
| 1 Year: | 1,148.30% |
Stock Price Performance
| 1 Year: | -17.15% |
| 6 Months: | - |
| 3 Months: | -8.12% |
| 1 Month: | -1.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)40.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 38.1% over 5 years.
CONS
- Trading 26.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RNA Atrium Therapeutics, Inc. R2K | 12.22 | -2.43 | $209.03M | 0.00% | -32.47% | -36.99% | 38.09% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 2.97M | 1.57M | 859.00K | 19.64M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 47.22M | 9.03M | 48.89M | 36.91M |
| Operating Income | -44.25M | -7.45M | -48.03M | -17.28M |
| EBITDA | -44.19M | -7.40M | -47.91M | -17.13M |
| Interest Expense | - | - | - | - |
| Pretax Income | -44.24M | -7.45M | -48.03M | -16.63M |
| Tax Provision | 1.95M | - | 34.00K | - |
| Net Income | -46.20M | -7.45M | -48.07M | -16.63M |
| Diluted EPS | - | -0.44 | - | -0.97 |
| R&D Expense | - | 6.94M | - | 16.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 9.76M | 10.90M | 18.62M |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 16.15M | 24.11M | 95.43M |
| Operating Income | -6.39M | -13.22M | -76.81M |
| EBITDA | -6.25M | -13.05M | -76.49M |
| Interest Expense | - | - | - |
| Pretax Income | -6.38M | -13.22M | -76.83M |
| Tax Provision | 0 | 11.91M | -142.00K |
| Net Income | -6.38M | -25.12M | -76.68M |
| Diluted EPS | -0.37 | -1.47 | -2.89 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 10.29M | 7.19M | 278.35M |
| Current Assets | 856.00K | 483.00K | 272.85M |
| Cash & Equivalents | - | - | 270.00M |
| Inventory | - | - | - |
| Receivables | 751.00K | 0 | - |
| Total Liabilities | 80.91M | 68.29M | 71.07M |
| Current Liabilities | 33.80M | 26.80M | 41.80M |
| Long Term Debt | - | - | - |
| Total Debt | 9.85M | 6.80M | 3.67M |
| Total Equity | -70.62M | -61.11M | 207.29M |
| Shares Outstanding | 17.11M | 17.11M | 17.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 56.39M | -22.55M | -41.13M |
| Investing Cash Flow | -320.00K | -266.00K | -1.45M |
| Financing Cash Flow | -56.07M | 22.82M | 42.57M |
| Capital Expenditure | -320.00K | -266.00K | -1.45M |
| Free Cash Flow | 56.07M | -22.82M | -42.57M |
| Net Change in Cash | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -65.4% | -121.3% | -412.6% |
| Net Margin % | -65.4% | -230.5% | -411.9% |
| ROE % | 9.0% | 41.1% | -37.0% |
| ROCE % | 27.2% | 67.4% | -32.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Price (T.Rowe) Associates Inc | 9.08% | 1.55M | $20.42M |
| 2 | Blackrock Inc. | 7.05% | 1.21M | $15.84M |
| 3 | RA Capital Management, L.P. | 5.05% | 864.10K | $11.36M |
| 4 | Vanguard Capital Management LLC | 3.66% | 626.87K | $8.24M |
| 5 | TIG Advisors, LLC | 3.55% | 607.55K | $7.99M |
| 6 | Pentwater Capital Management Lp | 3.52% | 602.65K | $7.92M |
| 7 | O'Connor Alternative Investments LLC | 3.38% | 578.01K | $7.60M |
| 8 | Sessa Capital IM, L.P. | 3.22% | 551.39K | $7.25M |
| 9 | Goldman Sachs Group Inc | 2.05% | 349.95K | $4.60M |
| 10 | Farallon Capital Management LLC | 2.04% | 349.36K | $4.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNA
Atrium's First PRKAG2 Trial to Evaluate Treatment for Disease Cause - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOQWNaLWlHaXNsSVB6TkdGTnVhNWlGLVYyVE1YN01CVkhFeWt2bjFTVTRlSzdQUDY0YXZwX3pfRjBqUUk5b0lfakZNaGp4U1VNN3ZqMS1WdlJXM1E4cVVKX0JCazdUOXZ5X3U0a3djdE9sdjF5Rm44UlJVcVd3SjJSM21jeVVKVmdHMzZTOV…
Enterprise value to revenue forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOelB5NWdFc2tMM09PaHdYLUVzSWdrX1c5Tm1nRnRSOUFXUWk5eGVUeFpDR3dWOTY4aWZ1TU1kczFXa0tTQXFzMEJMUktKZG15V1hMWHYwUkVxOGpVMzVXdmtXM2VIMU8wa19Wa25DNEM2SmR6Y1J4ZEFlR2I4Mm5BU2wyVUNPbkhOQlhLZV…
Atrium Therapeutics (Nasdaq: RNA) prepares Corventis PRKAG2 trial launch - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQMDV6R0RaTUdqc052djFrdTJwTlhUdU1Db2pabGZQVWZkLXR0dlpuSmFLd3hibE4xWEVKTFJ4WTQwUnAybzEtN2xZYTVsUWhmbUdad2NEMEM1WDFmckFxTFh5Z0RXSVpNMGt2OVMzeG1vQ05kUWlXM210dTYyTm94VFo5TVFnMmI1LXNIS0…
Avidity Biosciences Announces Expected Record Date for Spin-Off - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOS2ZBVjFGdXFnZGNhOWVlUVBvUjc2VGhjOGkwcC1iR21GM3RrQWdtRkdVMWFtckFqZW00S0F1eDI0MUxNZHJnQy1BRWZ2LWoyVjNndEpTM200TXNteENfNlRiMTlRaFlmSTJGbFBfWm9LMEU0R3hJd3Y1NHBCd1pnZ1Z6dlNNeG9QX09iQj…
Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions - MedCity News
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNN0hNMjgzanhNdV8weGJZNWw4RmZNMWt4QW8tQXYwbFZqZXFlM2tYOUdHdkRRbnZYeHNiNW55QU9pQVQ1di1UaGhwZEdzb1RhXzlaSjA0Sjk2Y2FuQVF1S1FlVVFTcHBZdXRJRG9CckRKLTVUOC1OSVNWX2o2dnd0T2drYkJnTEhUUjJLYk…
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNY3k2a3E5TUhXZzQ4Mlp1bElBNmxjUEd5U2I2eDBDNkl3WDdWN3Ywc0FfMVBVckc5SWFoOEJKMjlzSDY3cU85V0RxZVJ3U0laSElPSUp0dW5Jd3JGRG5sRzRMN1V6R0l4bllaenU5bTFxWjRfY01ZYndDdGRuUjRlaUFCTUJmNHphalZtby…
RNA — Frequently Asked Questions
What is the current share price of Atrium Therapeutics, Inc. (RNA)?
As of 2026-07-14 21:23 PDT, Atrium Therapeutics, Inc. (RNA) trades at $12.22 on NasdaqGS. Its 52-week range is $11.55 to $16.54.
What is the market capitalisation of RNA?
Atrium Therapeutics, Inc. (RNA) has a market capitalisation of $209.03M on NasdaqGS.
What is the P/E ratio of RNA?
RNA trades at a trailing price-to-earnings (P/E) ratio of -2.43. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 0.90.
What is the return on equity (ROE) of RNA?
RNA has a return on equity (ROE) of -36.99%. Its return on capital employed (ROCE) is -32.47%.
Is RNA a good stock to buy?
This page provides a data-driven analysis of Atrium Therapeutics, Inc. (RNA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.